OakChart

Assembly Biosciences Inc

ASMBHealthcare·Biotechnology·USA·Small·NASD·Nov 10 • 3:59 PM ET

21.350.00 (0.00%)
2026-11-11 14:59 CET
Market cap
434.70 USD m
Revenue, TTM
74.84 USD m
Net income, TTM
-0.04 USD m
Free cash flow, TTM
-38.57 USD m
EPS diluted, TTM
-0.07
P/E
-
Compare

Price

ASMB against its 20, 50 and 200-day averages
2050200beat
20.0025.0030.0035.00794K1.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ASMBclose 21.3520-day 20.3850-day 24.14200-day 26.9321.35

46.2% under 39.71 on 20 Nov 2025. Last 15 sessions, 14.2% high to low

Profile

ASMB
52-week range, 10% of the way up
19.2039.71

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

IndexRUT
Employees73
IPODec 17, 2010
Beta1.21
ATR, 14d1.11
Rel volume0.00
Short float23.69%
Insider own37.12%
Inst own66.77%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap434.70M
Enterprise Value116.69M
Income-0.04M
Sales74.84M
Book/sh15.40
Cash/sh15.73
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees73
IPODec 17, 2010

Ratios

P/E-
Forward P/E-
PEG-
P/S5.81
P/B1.39
P/C1.36
P/FCF-
EV/EBITDA-
EV/Sales1.56
Quick Ratio13.99
Current Ratio13.99
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.07
EPS next Y-3.05
EPS next Q-0.66
EPS this Y-10.58%
EPS next Y-401.32%
EPS next 5Y-
EPS past 3/5Y71.29% 51.83%
Sales past 3/5Y- -1.78%
EPS Y/Y TTM98.69%
Sales Y/Y TTM125.12%
EPS Q/Q84.64%
Sales Q/Q38.94%
EarningsAug 13 AMC
EPS/Sales Surpr.72.38% 55.53%

Ownership

Insider Own37.12%
Insider Trans-0.16%
Inst Own66.77%
Inst Trans20.39%
ROA-0.02%
ROE-0.03%
ROIC-0.01%
Gross Margin99.85%
Oper. Margin-11.75%
Profit Margin-0.06%
SMA204.78%
SMA50-11.56%
SMA200-20.73%
Trades-

Technical

Shs Outstand19.85M
Shs Float12.80M
Short Float23.69%
Short Ratio9.84
Short Interest3.03M
52W High39.71 -46.23%
52W Low19.20 11.20%
Volatility5.67% 5.29%
ATR (14)1.11
RSI (14)49.06
Beta1.21
Rel Volume0.00
Avg Volume308.34K
Volume0

Performance

Perf Week7.18%
Perf Month-6.24%
Perf Quarter-21.10%
Perf Half Y-30.73%
Perf YTD-37.22%
Perf Year-33.43%
Perf 3Y138.81%
Perf 5Y-39.48%
Perf 10Y-86.17%
Recom1.00
Target Price51.20
Prev Close21.35
Price21.35
Change %0.00%

Analyst ratings

latest 10 of 18
DateActionAnalystRating changeTargetImplied
Sep 01, 2026InitiatedUUBSBuy$52+143.6%
Sep 24, 2025InitiatedCCitizens JMPMkt Outperform$38+78.0%
Aug 18, 2025ResumedHH.C. WainwrightBuy$50+134.2%
Mar 25, 2025InitiatedGGuggenheimBuy$31+45.2%
Sep 20, 2024UpgradeJJefferiesHold → Buy$2 → $35+63.9%
Sep 13, 2021InitiatedHH.C. WainwrightNeutral$3.50-83.6%
Sep 02, 2021DowngradeWWilliam BlairOutperform → Mkt Perform
Mar 23, 2021DowngradeSSVB LeerinkOutperform → Mkt Perform
Nov 06, 2020DowngradeJJefferiesBuy → Hold$30 → $10-53.2%
Oct 19, 2020InitiatedTTruistBuy$55+157.6%

Peers

Mkt cap
TickerCompanyMkt cap
ABUSArbutus Biopharma Corp744.87M
ENTAEnanta Pharmaceuticals Inc326.79M
VIRVir Biotechnology Inc2.27B
ALGSAligos Therapeutics Inc20.15M
AVIRAtea Pharmaceuticals Inc337.28M
ARWRArrowhead Pharmaceuticals Inc6.96B
COCPCocrystal Pharma Inc19.84M
TRAWTraws Pharma Inc3.44M
INOInovio Pharmaceuticals Inc145.79M
NNVCNanoViricides Inc36.25M

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Bjorkquist Jeanette MPFO and PAONov 02 '26Sale19.6272714,26117,673Nov 03 04:50 PM
White Nicole SChief Manufacturing OfficerNov 02 '26Sale19.622,59350,86459,257Nov 03 04:45 PM
Gaggar AnujChief Medical OfficerNov 02 '26Sale19.622,59350,86453,800Nov 03 04:35 PM
Okazaki Jason ACEO and PresidentNov 02 '26Sale19.626,202121,658195,532Nov 03 04:30 PM
Nicole S. WhiteOfficerNov 02 '26Proposed Sale19.622,59350,864Nov 02 06:40 PM
Anuj GaggarOfficerNov 02 '26Proposed Sale19.622,59350,864Nov 02 06:35 PM
Jason A. OkazakiOfficerNov 02 '26Proposed Sale19.626,202121,658Nov 02 06:30 PM
Bjorkquist Jeanette MPFO and PAOJun 17 '26Sale23.252967414,560Jun 18 04:05 PM
Bjorkquist Jeanette MPFO and PAOMar 30 '26Sale26.693288,75511,089Mar 31 04:25 PM
White Nicole SChief Manufacturing OfficerMar 30 '26Sale26.691975,25837,477Mar 31 04:20 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 206
  • Assembly Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus (GlobeNewswire)
  • Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting 2026 (GlobeNewswire)
  • Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference (GlobeNewswire) -7.33%
  • Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program (GlobeNewswire) -6.83%
  • Loading…
  • Assembly Biosciences: Q2 Earnings Snapshot (Associated Press) +10.68% +10.02%
  • Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates (GlobeNewswire)
  • Assembly Biosciences Announces Upcoming Investor Conference Presentations (GlobeNewswire)
  • Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
  • Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.94%
  • Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases (GlobeNewswire)
  • Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 (GlobeNewswire)
  • Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.200-0.724-0.20013.378.604
2026Q12026-05-07-0.540-0.650-0.5378.219.274
2025Q42026-03-191.393-0.8561.39342.467.424
2025Q32025-11-10-0.720-0.821-0.72510.797.465
2025Q22025-08-06-1.330-1.730-1.3329.635.302
2025Q12025-05-08-1.170-1.600-1.1759.427.412
2024Q42025-03-20-1.540-1.795-1.5707.363.552
2024Q32024-11-07-1.510-2.303-1.5146.855.773
2024Q22024-08-08-1.980-2.230-1.9768.536.001
2024Q12024-05-08-1.660-3.230-1.6555.790.001
2023Q42024-03-28-1.860-2.820-1.9997.200.002
2023Q32023-11-08-3.240-2.820-3.2920.000.002
2023Q22023-08-09-3.840-3.360-3.8800.000.003
2023Q12023-05-04-4.440-4.160-4.4580.000.003
2022Q42023-03-22-5.400-4.760-5.5080.000.003
2022Q32022-11-08-5.760-4.440-5.7330.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-44.640-44.940-44.61815.9614.81
2020FY-21.000-18.672-21.05279.1182.01
2021FY-36.000-25.200-36.0046.257.41
2022FY-23.040-21.120-23.0760.000.00
2023FY-13.380-14.220-13.3767.160.00
2024FY-6.690-6.755-6.69128.5224.60
2025FY-0.550-3.750-0.55072.3037.14
2026FY--0.608--63.43
2027FY--3.049--42.65
2028FY--1.947--68.20
2029FY--3.093--27.30
2030FY--1.520--123.13

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-314009.075.0012.50
2026Q3S2026-08-314019.075.0012.50
2026Q3S2026-08-173017.935.0010.60
2026Q3S2026-08-143008.275.0010.60
2026Q3S2026-08-133008.275.0010.60
2026Q3S2026-06-083008.275.0010.60
2026Q3S2026-05-083018.275.0010.60
2026Q3S2026-04-012019.909.2010.60
2026Q3S2026-03-251019.209.209.20
2026Q3S2026-03-2010010.5910.5910.59
2026Q3S2026-01-2610010.5910.5910.59
2026Q3S2025-12-1911010.5910.5910.59
2026Q3S2025-11-2611010.6010.6010.60
2026Q3S2025-11-122109.308.0010.60

Estimate history

EPS, annual-28.92-47.76-44.618-21.052-36.004-23.076-13.376-6.691-0.546-0.0735
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.976-1.514-1.57-1.175-1.332-0.7251.393-0.537-0.205
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual9.01914.80415.96379.1056.25407.16328.5272.30374.84
Period201720182019202020212022202320242025TTM
Sales, quarterly8.5336.8457.3579.4199.62610.78942.4698.21313.374
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual1.6782.1252.7132.8364.014.0755.4837.45715.85519.85
Period201720182019202020212022202320242025MRQ
Shares, quarterly6.3466.3547.4577.6197.67215.81715.85515.89219.85
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue74.8472.3028.527.160.006.2579.1115.9614.80
Cost of Goods Sold Incl. D&A0.110.130.130.450.500.47---
Gross Profit74.7372.1728.396.71-0.505.79---
Selling, General and Administrative Excl. Other83.5384.2973.8171.3692.5298.19143.19116.08106.90
Research and Development63.5464.6855.8048.9069.1170.15106.8285.3672.74
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-8.80-12.12-45.42-64.65-93.02-92.40-64.78-100.61-92.73
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.001.1040.290.002.10-
Net Income Before Taxes-0.04-6.12-39.85-61.20-93.09-132.39-62.15-98.41-89.65
Income Taxes0.000.000.330.030.00-2.530.00-0.771.10
Consolidated Net Income-0.04-6.12-40.18-61.23-93.09-129.85-62.15-97.63-90.75
Net Income From Continuing Operations-0.04-6.12-40.18-61.23-93.09-129.85-62.15-97.63-90.75
Net Income-0.04-6.12-40.18-61.23-93.09-129.85-62.15-97.63-90.75
EPS (Recurring)-0.00-0.55-6.69-13.38-22.89-28.18-21.05-43.95-47.76
EPS (Basic, Before Extraordinaries)-0.07-0.55-6.69-13.38-23.08-36.00-21.05-44.62-47.76
EPS (Diluted)-0.07-0.55-6.69-13.38-23.08-36.00-21.05-44.62-47.76
EBITDA-8.69-11.99-45.29-64.20-92.52-91.93-64.08-100.12-92.09
Non-Operating Income (Expense)8.766.005.573.451.020.302.624.303.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.683.692.465.126.593.8221.8515.0122.50
Price To Sales Ratio6.925.273.326.29-16.122.7133.6634.84
Gross Margin99.8599.8299.5593.72-92.55---
Operating Margin-11.75-16.76-159.26-902.50--1,477.42-81.89-630.29-626.42
Net Margin-0.06-8.47-140.87-854.78--2,076.35-78.57-611.63-613.02
Shares Outstanding19.8515.867.465.484.074.012.842.712.12
Market Capitalization434.70434.70100.3043.1563.03112.12205.86666.14576.71

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue13.378.2142.4710.799.639.427.366.84
Cost of Goods Sold Incl. D&A0.020.030.030.030.030.030.030.03
Gross Profit13.358.1942.4410.769.599.397.336.81
Selling, General and Administrative Excl. Other19.7019.5622.6421.6420.6919.3318.8617.77
Research and Development14.9014.8717.2216.5516.0914.8214.2513.52
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.34-11.3719.80-10.88-11.09-9.94-11.53-10.96
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-3.86-9.0822.09-9.20-10.20-8.82-10.41-9.61
Income Taxes0.000.000.000.000.000.00-0.080.00
Consolidated Net Income-3.86-9.0822.09-9.20-10.20-8.82-10.34-9.61
Net Income From Continuing Operations-3.86-9.0822.09-9.20-10.20-8.82-10.34-9.61
Net Income-3.86-9.0822.09-9.20-10.20-8.82-10.34-9.61
EPS (Recurring)-0.20-0.541.39-0.72-1.33-1.17-1.57-1.51
EPS (Basic, Before Extraordinaries)-0.20-0.541.39-0.72-1.33-1.17-1.57-1.51
EPS (Diluted)-0.20-0.541.39-0.72-1.33-1.17-1.57-1.51
EBITDA-6.32-11.3419.83-10.85-11.06-9.91-11.50-10.92
Non-Operating Income (Expense)2.492.292.291.690.901.121.121.34
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.421.120.481.670.830.710.590.80
Price To Sales Ratio6.926.607.468.734.172.233.643.39
Gross Margin99.8599.6899.9299.7099.6799.6599.5799.52
Operating Margin-47.44-138.4446.62-100.87-115.24-105.54-156.75-160.06
Net Margin-28.84-110.5452.01-85.23-105.94-93.62-140.48-140.44
Shares Outstanding19.8515.8915.8615.827.677.627.466.35
Market Capitalization434.70440.19537.94398.34138.3971.73100.3096.07

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments248.11112.08130.2591.61146.63216.41274.04218.08119.95
Short Term Receivables2.470.400.040.940.341.233.372.432.27
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.973.023.504.417.246.855.361.990.90
Total Current Assets254.55115.50133.7996.97154.20224.49282.78222.50123.12
Net Property, Plant & Equipment2.733.352.723.947.1810.7313.800.560.86
Total Investments and Advances0.000.000.000.0027.970.000.000.003.35
Intangible Assets----0.0041.6441.6441.6441.64
Deferred Tax Assets0.700.810.650.811.547.267.98--
Other Assets0.310.310.310.891.706.391.683.350.34
Total Assets258.29119.97137.47102.61192.60290.51347.89268.05169.30
Short Term Debt Incl. Current Port. of LT Debt0.570.461.223.363.153.403.190.000.00
Accounts Payable1.170.580.462.492.664.601.733.692.12
Other Current Liabilities47.0446.7637.5410.4410.2616.4319.5214.7811.37
Total Current Liabilities48.7847.8039.2316.3016.0724.4324.4418.4713.49
Long Term Debt2.062.631.120.103.336.729.080.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.700.810.650.811.549.7910.513.252.14
Other Liabilities0.0035.3855.382.732.738.9930.6435.6740.56
Total Liabilities51.5486.6196.3719.9423.6849.9374.6757.3956.18
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity206.7533.3641.1082.66168.93240.58273.22210.65113.12
Total Shareholders Equity206.7533.3641.1082.66168.93240.58273.22210.65113.12
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity206.7533.3641.1082.66168.93240.58273.22210.65113.12
Total Liabilities & Stockholders Equity258.29119.97137.47102.61192.60290.51347.89268.05169.30
Book Value Per Share13.044.477.5020.2942.1384.84100.7099.1567.41
Tangible Book Value Per Share13.044.477.5020.2942.1370.1685.3579.5542.60
Full-Time Employees737365681021391159579
Price to Book Ratio1.393.861.030.620.660.862.442.7416.69
Return on Assets-3.24-31.21-51.01-63.07-53.76-19.47-31.70-41.50-32.02
Return on Equity-5.10-107.92-98.95-74.00-63.42-24.19-40.36-56.06-44.36
Return on Invested Capital-2.93-111.64-145.02-112.48-75.39-25.13-34.59-43.08-37.84
Quick Ratio5.222.423.415.959.599.1911.5712.059.13
Current Ratio5.222.423.415.959.599.1911.5712.059.13

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-0.04-6.12-40.18-61.23-93.09-129.85-62.15-97.63-90.75
Depreciation0.110.130.130.450.500.470.690.490.64
Other Funds (Non Cash)4.463.180.887.1810.2549.9228.8123.3728.26
Funds from Operations4.53-2.81-39.17-53.60-82.34-82.00-32.65-74.54-60.75
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-43.01-38.28-11.9576.34-2.12-11.40-30.31-9.53-4.21
Cash from Operating Activities-38.48-41.09-51.1222.74-84.46-93.40-62.96-84.07-64.96
Capital Expenditures-0.09-0.07-0.03-0.26-0.10-3.10-2.22-1.55-0.34
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.020.000.860.000.00-
Purchase or Sale of Investments-234.43-113.4040.20-68.9190.7428.7570.29-48.76-135.06
Purchase of Investments-401.28-229.83-90.50-133.92-27.58-160.45-193.19-281.33-183.94
Sale Or Maturity of Investments166.85116.43130.7065.02118.33189.20263.48232.5748.88
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-234.51-113.4740.17-69.1490.6426.5268.07-50.32-135.40
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock281.27174.6729.4513.820.6153.067.60139.65159.79
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock281.27174.6729.4513.820.6153.067.60139.65159.79
Proceedsfrom Stock Options122.10123.600.000.000.000.005.45135.41155.83
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities281.27174.6729.4513.820.6153.067.60139.65159.79
Net Change in Cash8.2820.1118.50-32.586.79-13.8212.715.26-40.56
Free Cash Flow-38.57-41.16-51.1522.49-84.56-96.49-63.43-85.62-65.30
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow---2.00-----
Deferred Taxes & Investment Tax Credit-0.000.000.000.00-2.530.00-0.771.10

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments320.36226.60248.11232.5674.9891.03
Short Term Receivables2.921.452.471.910.300.40
Inventories0.000.000.000.000.000.00
Other Current Assets4.704.563.972.342.194.10
Total Current Assets327.98232.61254.55236.8177.4795.53
Net Property, Plant & Equipment2.542.582.732.873.003.18
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets--0.70---
Other Assets0.310.310.310.310.310.31
Total Assets330.83235.51258.29240.0080.7899.02
Short Term Debt Incl. Current Port. of LT Debt0.610.590.570.550.530.53
Accounts Payable1.181.131.171.680.740.88
Other Current Liabilities21.6533.2847.0451.1546.0245.23
Total Current Liabilities23.4535.0048.7853.3847.2946.63
Long Term Debt1.741.902.062.212.352.49
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.70---
Other Liabilities0.000.000.001.7213.0422.76
Total Liabilities25.1836.9051.5457.3062.6871.88
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity305.65198.61206.75182.6918.1027.13
Total Shareholders Equity305.65198.61206.75182.6918.1027.13
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity305.65198.61206.75182.6918.1027.13
Total Liabilities & Stockholders Equity330.83235.51258.29240.0080.7899.02
Book Value Per Share15.4012.5013.0411.552.363.56
Tangible Book Value Per Share15.4012.5013.0411.552.363.56
Full-Time Employees--73---
Price to Book Ratio1.392.132.9410.855.092.14
Return on Assets-0.02-3.82-3.24-22.66-39.74-36.47
Return on Equity-0.03-5.66-5.10-36.94-147.64-133.65
Return on Invested Capital-1.25-4.5310.58-4.97-49.87-29.77
Quick Ratio13.996.655.224.441.642.05
Current Ratio13.996.655.224.441.642.05

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.86-9.0822.09-9.20-10.20-8.82
Depreciation0.020.030.030.030.030.03
Other Funds (Non Cash)1.850.530.831.250.670.42
Funds from Operations-1.99-8.5222.96-7.92-9.49-8.36
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-13.50-13.57-8.72-7.22-7.27-15.08
Cash from Operating Activities-15.49-22.1014.24-15.13-16.76-23.44
Capital Expenditures0.00-0.02-0.02-0.040.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-92.08-5.3621.25-158.2316.996.59
Purchase of Investments-145.84-62.96-11.55-180.93-17.51-19.85
Sale Or Maturity of Investments53.7657.6032.8022.7034.5026.43
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-92.08-5.3821.22-158.2716.996.59
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock108.730.150.46171.930.361.92
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock108.730.150.46171.930.361.92
Proceedsfrom Stock Options0.420.00-1.92123.601.920.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities108.730.150.46171.930.361.92
Net Change in Cash1.17-27.3335.92-1.470.59-14.93
Free Cash Flow-15.49-22.1214.21-15.18-16.76-23.44

Revenue breakdown

Pharmaceutical Preparations2024: 28.52M 2025: 72.30M
United States2024: 28.52M 2025: 72.30M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3023.69%3.0M12.8M289.53K
2026-10-1522.76%2.9M12.8M284.89K
2026-09-3019.34%2.8M14.6M268.56K
2026-09-1514.36%2.1M14.6M258.97K
2026-08-3116.56%2.1M12.8M236.70K
2026-08-1418.08%2.3M12.8M219.07K
2026-07-3118.73%2.3M12.5M208.86K
2026-07-1518.54%2.3M12.5M201.65K
2026-06-3019.31%2.4M12.5M189.90K
2026-06-1514.96%1.9M12.5M140.64K
2026-05-2913.50%1.7M12.5M120.88K
2026-05-1514.72%1.5M10.5M107.82K
2026-04-3015.05%1.6M10.4M94.47K
2026-04-1514.82%1.5M10.3M95.84K
2026-03-3114.57%1.5M10.5M97.35K
2026-03-1314.46%1.5M10.5M117.41K
2026-02-2714.10%1.5M10.5M119.72K
2026-02-1314.16%1.5M10.5M124.51K
2026-01-3015.41%1.5M10.0M128.24K
2026-01-1515.68%1.6M10.0M131.24K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.004.208.700.004.2170.000.000.810-0.3320.010
call17.501.706.000.002.9910.000.000.749-0.3090.011
call20.000.205.001.703.2002250.000.666-0.2610.013
call22.500.004.901.553.8592710.000.586-0.2570.014
call25.000.004.900.454.42319.000.000.559-0.3120.014
call30.000.004.900.505.2821000.000.517-0.3760.014
call35.000.004.900.355.92843.000.000.492-0.4220.014
call40.000.004.900.406.4461.000.000.475-0.4580.014
put15.000.004.900.006.8560.000.00-0.190-0.3310.010
put17.500.004.900.005.4260.000.00-0.251-0.3070.011
put20.000.004.901.604.19185.000.00-0.334-0.2590.013
put22.500.855.001.953.11124.000.00-0.414-0.2540.014
put25.002.606.003.102.6138.000.00-0.441-0.3090.014
put30.006.5011.006.543.4592.000.00-0.483-0.3720.014
put35.0011.5016.000.004.0870.000.00-0.508-0.4180.014
put40.0016.5021.000.004.5880.000.00-0.525-0.4540.014

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-20S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-148-K/A2026-08-13SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-04SCHEDULE 13G/ASEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-03-29SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-03-29SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-03-29SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-03-29SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-03-29SEC
2026-06-058-KCurrent report2026-06-04SEC
2026-05-274Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-27SCHEDULE 13D/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100237.65K4
2026-100000
2026-090000
2026-080000
2026-070000
2026-06006741
2026-050000
2026-040000
2026-030014.01K2
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GILEAD SCIENCES, INC.24.44%
FARALLON CAPITAL MANAGEMENT, L.L.C.8.10%
Paradigm Biocapital Advisors LP7.84%
Commodore Capital LP7.14%
RA CAPITAL MANAGEMENT, L.P.5.15%
Jupiter Topco LLC4.29%
BlackRock, Inc.3.87%
Parkman Healthcare Partners LLC3.64%
VANGUARD CAPITAL MANAGEMENT LLC2.82%
Point72 Asset Management, L.P.2.32%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.09%
iShares Russell 2000 ETF1.24%
VANGUARD EXTENDED MARKET INDEX FUND0.67%
abrdn Healthcare Investors0.65%
Fidelity Small Cap Index Fund0.54%
iShares Russell 2000 Value ETF0.45%
abrdn Life Sciences Investors0.39%
Fidelity Extended Market Index Fund0.28%
VANGUARD RUSSELL 2000 INDEX FUND0.28%
Franklin Biotechnology Discovery Fund0.22%

OakChart. ASMB. Cached 15 minutes.